Harmony Biosciences has a Market Access professional named Julie Brown leading a team focused on product access for patients.
Public source
Publisher name
Public post
At Harmony Biosciences, Julie Brown leads a team of Market Access professionals with a clear focus: helping to ensure product access for patients. Julie and her team nav…
Company
Harmony Biosciences
Committed to developing and delivering new therapeutic options for people living with rare neurological diseases.
- Industry
- Pharmaceutical Manufacturing
- Location
- Plymouth Meeting, US
- Company size
- 201–500 employees
About Harmony Biosciences
Harmony Biosciences is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for people living with rare and other neurological diseases with unmet medical needs. Guided by empathy, driven by science, and focused on innovation, we combine a strong commercial foundation with a growing pipeline of differentiated programs designed to advance treatment across multiple neurological conditions. By creating long-term value through scientific innovation, operational excellence, and disciplined execution, we invest in our people, our pipeline, and our mission to help improve patients’ lives. Follow us: Instagram → @harmony_biosciences X → @harmonybio #InHarmony #EmpathyAndInnovation View community guidelines: http://bit.ly/4v2Exc8
See moreLatest activity
Latest activity from Harmony Biosciences
5 signals
Presence & Recognition
Harmony Biosciences participated in the Underdog Series panel discussion hosted by Life Science Cares Philadelphia featuring Christopher Molineaux Nyree Oliver and Dan Rhoton on how the company contributes to the Greater Philadelphia community.
Presence & Recognition
Harmony Biosciences announced that it will present encore data from its epilepsy pipeline at the 16th European Epilepsy Congress hosted by the International League Against Epilepsy in Athens, Greece.
Presence & Recognition
Harmony Biosciences President and CEO Jeffrey M. Dayno, Chief Operating Officer Peter Anastasiou, and Chief Medical and Scientific Officer Kumar Budur, M.D., spoke with Fierce Biotech to discuss the growing momentum around orexin agonists and their potential across CNS disorders.
Discover more
Similar signals
Similar public activity from other companies.
People
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is recruiting across a number of positions for the team.
People
Ipsen
Ipsen appointed Alison O'Malley as the new Northeast Field Access Director for Rare Disease, Liver with IPSEN Biopharmaceuticals.
People
Lundbeck
Lundbeck is hiring for a number of Rare Epilepsy Market Lead positions across the U.S.
People
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is growing its team with a need for a Bachelor's degree, 2-4 years of pharma/life sciences sales experience in neuroscience, psychiatry, ADHD, and pediatric psychiatry.
People
Blue Earth Diagnostics, Inc. (U.S.)